Product Information
THEOPHYLLINE ER 300 MG TABLET is a generic product labeled by Leading Pharma, LLC, priced at $0.3295 per EA under NDC 69315022601. Its NADAC has been published 171 times since Jun 28, 2023.
FDA first approved this application on Jan 30, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Leading Pharma, LLCNDC
69315022601
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
THEOPHYLLINEApproval Type
Generic (ANDA)
FDA Application
ANDA214950FDA Approved
1/30/2023
TE Code
AB
On Market Since
5/15/2023
Pharmacological Classes
Price Statistics
The NADAC for THEOPHYLLINE ER 300 MG TABLET has been published 171 times since Jun 28, 2023, and over the history we have for it it has declined 84.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3295 per EA |
|---|---|
| All-time high | $2.1654 (Aug 16, 2023) |
| All-time low | $0.3196 (May 20, 2026) |
| 52-week high | $0.4924 |
| 52-week low | $0.3196 |
| Median price | $0.5967 |
| Average price | $0.9209 |
| Largest weekly change | +88.5% (Aug 21, 2024) |
| Weeks tracked | 171 |
| Tracking since | Jun 28, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the THEOPHYLLINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Leading Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
THEOPHYLLINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Methylxanthine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THEOPHYLLINE ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for THEOPHYLLINE ER 300 MG TABLET, manufactured by Leading Pharma, LLC, is $0.3295 per EA (NDC 69315022601), effective Sep 30, 2026.
How has the price of THEOPHYLLINE ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for THEOPHYLLINE ER 300 MG TABLET has declined 84.6%. It has been tracked across 171 weekly CMS publications since Jun 28, 2023.
What are the highest and lowest recorded NADAC prices for THEOPHYLLINE ER 300 MG TABLET?
Since Jun 28, 2023, the NADAC for THEOPHYLLINE ER 300 MG TABLET has ranged from a low of $0.3196 (May 20, 2026) to a high of $2.1654 (Aug 16, 2023), with a median of $0.5967 per EA.
Are there cheaper alternatives to THEOPHYLLINE ER 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of THEOPHYLLINE ER 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures THEOPHYLLINE ER 300 MG TABLET?
THEOPHYLLINE ER 300 MG TABLET (NDC 69315022601) is labeled by Leading Pharma, LLC, and CMS classifies it as a generic product.